Abstract
The KDM5 family of histone demethylases catalyzes the demethylation of histone H3 on lysine 4 (H3K4) and is required for the survival of drug-tolerant persister cancer cells (DTPs). Here we report the discovery and characterization of the specific KDM5 inhibitor CPI-455. The crystal structure of KDM5A revealed the mechanism of inhibition of CPI-455 as well as the topological arrangements of protein domains that influence substrate binding. CPI-455 mediated KDM5 inhibition, elevated global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents. These findings show that pretreatment of cancer cells with a KDM5-specific inhibitor results in the ablation of a subpopulation of cancer cells that can serve as the founders for therapeutic relapse.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting epigenetic regulators to overcome drug resistance in cancers
Signal Transduction and Targeted Therapy Open Access 17 February 2023
-
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution
Cancer and Metastasis Reviews Open Access 09 February 2023
-
Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis
Experimental & Molecular Medicine Open Access 12 December 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout






References
Greer, E.L. & Shi, Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 13, 343–357 (2012).
McGrath, J. & Trojer, P. Targeting histone lysine methylation in cancer. Pharmacol. Ther. 150, 1–22 (2015).
Gonzalez-Perez, A., Jene-Sanz, A. & Lopez-Bigas, N. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol. 14, r106 (2013).
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).
Zack, T.I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140 (2013).
Herz, H.M., Garruss, A. & Shilatifard, A. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem. Sci. 38, 621–639 (2013).
Kooistra, S.M. & Helin, K. Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell Biol. 13, 297–311 (2012).
Upadhyay, A.K., Horton, J.R., Zhang, X. & Cheng, X. Coordinated methyl-lysine erasure: structural and functional linkage of a Jumonji demethylase domain and a reader domain. Curr. Opin. Struct. Biol. 21, 750–760 (2011).
Rose, N.R., McDonough, M.A., King, O.N., Kawamura, A. & Schofield, C.J. Inhibition of 2-oxoglutarate dependent oxygenases. Chem. Soc. Rev. 40, 4364–4397 (2011).
Lin, W. et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc. Natl. Acad. Sci. USA 108, 13379–13386 (2011).
Catchpole, S. et al. PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells. Int. J. Oncol. 38, 1267–1277 (2011).
Yamane, K. et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell 25, 801–812 (2007).
Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23, 811–825 (2013).
Klose, R.J., Kallin, E.M. & Zhang, Y. JmjC-domain-containing proteins and histone demethylation. Nat. Rev. Genet. 7, 715–727 (2006).
Chen, Z. et al. Structural insights into histone demethylation by JMJD2 family members. Cell 125, 691–702 (2006).
Dann, C.E. III, Bruick, R.K. & Deisenhofer, J. Structure of factor-inhibiting hypoxia-inducible factor 1: an asparaginyl hydroxylase involved in the hypoxic response pathway. Proc. Natl. Acad. Sci. USA 99, 15351–15356 (2002).
McDonough, M.A. et al. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc. Natl. Acad. Sci. USA 103, 9814–9819 (2006).
Rasmussen, P.B. & Staller, P. The KDM5 family of histone demethylases as targets in oncology drug discovery. Epigenomics 6, 277–286 (2014).
Thinnes, C.C. et al. Targeting histone lysine demethylases—progress, challenges, and the future. Biochim. Biophys. Acta 1839, 1416–1432 (2014).
Sayegh, J. et al. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J. Biol. Chem. 288, 9408–9417 (2013).
Sengoku, T. & Yokoyama, S. Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A. Genes Dev. 25, 2266–2277 (2011).
Kruidenier, L. et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404–408 (2012).
Heinemann, B. et al. Inhibition of demethylases by GSK-J1/J4. Nature 514, E1–E2 (2014).
Christensen, J. et al. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 128, 1063–1076 (2007).
Iwase, S. et al. The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 128, 1077–1088 (2007).
Klose, R.J. et al. The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128, 889–900 (2007).
Seward, D.J. et al. Demethylation of trimethylated histone H3 Lys4 in vivo by JARID1 JmjC proteins. Nat. Struct. Mol. Biol. 14, 240–242 (2007).
Ong, S.E., Mittler, G. & Mann, M. Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. Nat. Methods 1, 119–126 (2004).
Fodor, B.D. et al. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev. 20, 1557–1562 (2006).
Tu, S. et al. The ARID domain of the H3K4 demethylase RBP2 binds to a DNA CCGCCC motif. Nat. Struct. Mol. Biol. 15, 419–421 (2008).
Iwahara, J., Iwahara, M., Daughdrill, G.W., Ford, J. & Clubb, R.T. The structure of the Dead ringer-DNA complex reveals how AT-rich interaction domains (ARIDs) recognize DNA. EMBO J. 21, 1197–1209 (2002).
Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583–594 (2010).
Raha, D. et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res. 74, 3579–3590 (2014).
Horton, J.R. et al. Enzymatic and structural insights for substrate specificity of a family of jumonji histone lysine demethylases. Nat. Struct. Mol. Biol. 17, 38–43 (2010).
Garapaty-Rao, S. et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem. Biol. 20, 1329–1339 (2013).
Maile, T.M. et al. Mass spectrometric quantification of histone posttranslational modifications by a hybrid chemical labeling method. Mol. Cell. Proteomics 14, 1148–1158 (2015).
MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966–968 (2010).
Garcia, B.A. et al. Chemical derivatization of histones for facilitated analysis by mass spectrometry. Nat. Protoc. 2, 933–938 (2007).
Olsen, J.V. et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics 4, 2010–2021 (2005).
Bradley, W.D. et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem. Biol. 21, 1463–1475 (2014).
Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997).
Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
Acknowledgements
We thank the Genentech Structural Biology Expression Group and J. Wu for additional protein expression and purification, as well as other members of the KDM5 team. We also thank J. Settleman for comments on the manuscript and B. Haley for short hairpin design. We thank Shamrock Structures, LLC, for diffraction data collection from beamline 08ID-1 at the Canadian Light Source, supported by the Natural Sciences and Engineering Research Council of Canada, the National Research Council Canada, the Canadian Institutes of Health Research, the Province of Saskatchewan, Western Economic Diversification Canada, and the University of Saskatchewan, and from beamline 5.0.2 of the Advanced Light Source. The Berkeley Center for Structural Biology is supported in part by the National Institutes of Health, National Institute of General Medical Sciences, and the Howard Hughes Medical Institute. The Advanced Light Source is supported by the Director, Office of Science and Office of Basic Energy Sciences, of the US Department of Energy under Contract No. DE-AC02-05CH11231.
Author information
Authors and Affiliations
Contributions
M.V. and J.R.K. were involved in the crystallography efforts. V.S.G., A.G., K.E.W., P.G., W.M., E.M.F., F.L., S.O., A.G.C., Y.L., C.B., S.B., R.T.C., B.K.A. and J.-C.H. were involved in assay development, protein production, biochemical assays, and the development and execution of cell-based assays. F.L. made the KDM5A constructs. S.A., C.A.T., C.W., G.D.G., H.K., T.L., M.C. and R.P. were involved in the design and execution of DTP and ALDH assays. M.W., Y.Y., E.J. and G.V.H. were involved in the in vivo analysis of tumors in patients and mice. T.K.C., T.M.M., D.A. and J.B. participated in histone MS analysis. J.R.K., P.T. and M.C. contributed equally, oversaw all experiments and wrote the manuscript.
Corresponding authors
Ethics declarations
Competing interests
V.S.G., S.A., K.E.W., W.M., J.B., S.O., C.B., S.B., R.T.C. and P.T. are employees and shareholders of Constellation Pharmaceutical Inc. P.G., F.L., J.-C.H. and B.K.A. are shareholders of Constellation Pharmaceutical Inc. All other authors are employees of Genentech Inc. and may hold stock in the Roche Group.
Supplementary information
Supplementary Text and Figures
Supplementary Results, Supplementary Tables 1–9 and Supplementary Figures 1–3. (PDF 2866 kb)
Supplementary Note
Synthetic Procedures (PDF 578 kb)
Rights and permissions
About this article
Cite this article
Vinogradova, M., Gehling, V., Gustafson, A. et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol 12, 531–538 (2016). https://doi.org/10.1038/nchembio.2085
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.2085
This article is cited by
-
Rational combinations of targeted cancer therapies: background, advances and challenges
Nature Reviews Drug Discovery (2023)
-
Targeting epigenetic regulators to overcome drug resistance in cancers
Signal Transduction and Targeted Therapy (2023)
-
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution
Cancer and Metastasis Reviews (2023)
-
E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter
Cancer Cell International (2022)
-
JMJD family proteins in cancer and inflammation
Signal Transduction and Targeted Therapy (2022)